Phibro Animal Health Corporation (PAHC) 10-Year Financial Performance & Capital Metrics

PAHC • • Industrial / General

HealthcareSpecialty & Generic PharmaAnimal Health ProductsLivestock Health

AboutPhibro Animal Health Corporation develops, manufactures, and supplies a range of animal health and mineral nutrition products for livestock primarily in the United States. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets products for a range of food animals, including poultry, swine, beef and dairy cattle, and aquaculture. Its animal health products also comprise antibacterials that are biological or chemical products used in the animal health industry to treat or to prevent bacterial diseases; anticoccidials primarily used to prevent and control the disease coccidiosis in poultry and cattle; anthelmintics to treat infestations of parasitic intestinal worms; and anti-bloat treatment products for cattle to control bloat in animals grazing on legume or wheat-pasture. In addition, the company offers nutritional specialty products, which enhance nutrition to help improve health and performance; and vaccines to prevent diseases primarily for the poultry and swine markets. Further, it manufactures and markets formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds; and various specialty ingredients for use in the personal care, industrial chemical, and chemical catalyst industries. The company sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle integrators, as well as through commercial animal feed manufacturers, wholesalers, and distributors. It operates in the United States, Latin America, Canada, Europe, the Middle East, Africa, and the Asia Pacific. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was incorporated in 2014 and is headquartered in Teaneck, New Jersey.Show more

Revenue $1.3B +27.4%
EBITDA $156M +74.4%
Net Income $48M +1897.7%
EPS (Diluted) 1.19 +1883.3%
Gross Margin 30.85% +0.3%
EBITDA Margin 12.04% +36.9%
Operating Margin 8.52% +62.7%
Net Margin 3.72% +1468.4%
ROE 17.8% +1886.1%
ROIC 9.8% +79.3%
Debt/Equity 2.67 +30.2%
Interest Coverage 3.32 +36.9%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓High quality earnings: Operating CF exceeds net income
✓Strong 5Y sales CAGR of 10.1%

✗Weaknesses

✗High debt to equity ratio of 2.7x

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y5.64%

5Y10.12%

3Y11.22%

TTM33.71%

Profit (Net Income) CAGR

10Y-2.2%

5Y7.54%

3Y-0.62%

TTM289.61%

EPS CAGR

10Y-2.35%

5Y7.47%

3Y-0.55%

TTM287.31%

ROCE

10Y Avg13.35%

5Y Avg10.14%

3Y Avg9.37%

Latest11.97%

Peer Comparison

Livestock Health

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
PAHCPhibro Animal Health Corporation	819.13M	40.06	33.66	27.37%	4.85%	21.76%	5.11%	2.67
ZYBTZhengye Biotechnology Holding Limited	52.6M	1.11		-11.95%	6.07%	3.27%	25.23%	0.25

Profit & Loss

	Jun 2016	Jun 2017	Jun 2018	Jun 2019	Jun 2020	Jun 2021	Jun 2022	Jun 2023	Jun 2024	Jun 2025
Sales/Revenue+	751.5M	764.3M	820M	828M	800.35M	833.35M	942.26M	977.89M	1.02B	1.3B
Revenue Growth %	0%	0.02%	0.07%	0.01%	-0.03%	0.04%	0.13%	0.04%	0.04%	0.27%
Cost of Goods Sold+	512.5M	516M	553.1M	563.4M	543.47M	561.97M	656.86M	679.65M	704.59M	896.27M
COGS % of Revenue	0.68%	0.68%	0.67%	0.68%	0.68%	0.67%	0.7%	0.7%	0.69%	0.69%
Gross Profit+	239M	248.3M	266.9M	264.6M	256.88M	271.38M	285.4M	298.24M	313.09M	399.94M
Gross Margin %	0.32%	0.32%	0.33%	0.32%	0.32%	0.33%	0.3%	0.3%	0.31%	0.31%
Gross Profit Growth %	0.01%	0.04%	0.07%	-0.01%	-0.03%	0.06%	0.05%	0.04%	0.05%	0.28%
Operating Expenses+	153.3M	150.3M	168M	181.4M	187.69M	196.51M	206.41M	226.39M	259.78M	289.48M
OpEx % of Revenue	0.2%	0.2%	0.2%	0.22%	0.23%	0.24%	0.22%	0.23%	0.26%	0.22%
Selling, General & Admin	153.3M	150.3M	168M	181.4M	187.69M	196.51M	206.41M	226.39M	259.78M	289.48M
SG&A % of Revenue	0.2%	0.2%	0.2%	0.22%	0.23%	0.24%	0.22%	0.23%	0.26%	0.22%
Research & Development	11.03M	9.44M	10M	12.08M	0	0	0	0	0	0
R&D % of Revenue	0.01%	0.01%	0.01%	0.01%	-	-	-	-	-	-
Other Operating Expenses	0	0	0	0	0	0	0	0	0	0
Operating Income+	85.7M	97.9M	98.9M	73.3M	69.19M	74.87M	78.99M	71.85M	53.31M	110.47M
Operating Margin %	0.11%	0.13%	0.12%	0.09%	0.09%	0.09%	0.08%	0.07%	0.05%	0.09%
Operating Income Growth %	-0.02%	0.14%	0.01%	-0.26%	-0.06%	0.08%	0.06%	-0.09%	-0.26%	1.07%
EBITDA+	109.15M	123.9M	125.84M	100.86M	101.53M	106.75M	111.69M	105.86M	89.49M	156.07M
EBITDA Margin %	0.15%	0.16%	0.15%	0.12%	0.13%	0.13%	0.12%	0.11%	0.09%	0.12%
EBITDA Growth %	-0%	0.14%	0.02%	-0.2%	0.01%	0.05%	0.05%	-0.05%	-0.15%	0.74%
D&A (Non-Cash Add-back)	23.45M	26M	26.94M	27.56M	32.34M	31.88M	32.7M	34.01M	36.18M	45.6M
EBIT	93.61M	97.42M	100.79M	85.18M	69.24M	78.33M	84.43M	72.02M	32.89M	101.24M
Net Interest Income+	-16.59M	-14.91M	-11.91M	-11.78M	-12.55M	-9.56M	-11.29M	-14.59M	-17.5M	-30.63M
Interest Income	256K	1.97M	1.69M	1.9M	1.76M	838K	816K	3.35M	4.47M	2.62M
Interest Expense	16.85M	16.87M	13.6M	13.68M	14.3M	10.4M	12.1M	17.95M	21.97M	33.25M
Other Income/Expense	-19.44M	-17.39M	-10.86M	-11.72M	-13.68M	-8.4M	-6.66M	-17.78M	-42.4M	-42.47M
Pretax Income+	76.8M	80.5M	88.1M	71.5M	55.51M	66.47M	72.33M	54.07M	10.92M	67.99M
Pretax Margin %	0.1%	0.11%	0.11%	0.09%	0.07%	0.08%	0.08%	0.06%	0.01%	0.05%
Income Tax+	-6M	15.9M	23.2M	16.8M	21.96M	12.08M	23.15M	21.46M	8.5M	19.73M
Effective Tax Rate %	1.08%	0.8%	0.74%	0.77%	0.6%	0.82%	0.68%	0.6%	0.22%	0.71%
Net Income+	82.7M	64.6M	64.9M	54.7M	33.55M	54.38M	49.17M	32.61M	2.42M	48.26M
Net Margin %	0.11%	0.08%	0.08%	0.07%	0.04%	0.07%	0.05%	0.03%	0%	0.04%
Net Income Growth %	0.37%	-0.22%	0%	-0.16%	-0.39%	0.62%	-0.1%	-0.34%	-0.93%	18.98%
Net Income (Continuing)	82.73M	64.61M	64.88M	54.71M	33.55M	54.38M	49.17M	32.61M	2.42M	48.26M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	2.07	1.61	1.61	1.35	0.83	1.34	1.21	0.81	0.06	1.19
EPS Growth %	0.37%	-0.22%	0%	-0.16%	-0.39%	0.61%	-0.1%	-0.33%	-0.93%	18.83%
EPS (Basic)	2.11	1.63	1.61	1.35	0.83	1.34	1.21	0.81	0.06	1.19
Diluted Shares Outstanding	40M	40M	40.4M	40.52M	40.5M	40.5M	40.5M	40.5M	40.52M	40.7M
Basic Shares Outstanding	39.3M	39.5M	40.2M	40.41M	40.5M	40.5M	40.5M	40.5M	40.5M	40.5M
Dividend Payout Ratio	0.19%	0.24%	0.25%	0.34%	0.58%	0.36%	0.4%	0.6%	8.05%	0.4%

Balance Sheet

	Jun 2016	Jun 2017	Jun 2018	Jun 2019	Jun 2020	Jun 2021	Jun 2022	Jun 2023	Jun 2024	Jun 2025
Total Current Assets+	342.83M	363.67M	415.46M	466.16M	451.84M	498.91M	566.23M	585.72M	601M	810.61M
Cash & Short-Term Investments	33.6M	56.08M	79.17M	81.57M	91.34M	93.21M	91.25M	81.28M	114.61M	77.04M
Cash Only	33.6M	56.08M	29.17M	57.57M	36.34M	50.21M	74.25M	41.28M	70.61M	68.04M
Short-Term Investments	0	0	50M	24M	55M	43M	17M	40M	44M	9M
Accounts Receivable	123.79M	125.85M	135.74M	159.02M	126.52M	146.85M	166.54M	163.48M	169.45M	227.98M
Days Sales Outstanding	60.12	60.1	60.42	70.1	57.7	64.32	64.51	61.02	60.78	64.2
Inventory	167.69M	161.23M	178.17M	198.32M	196.66M	216.31M	259.16M	277.57M	265.91M	444.43M
Days Inventory Outstanding	119.43	114.05	117.58	128.48	132.08	140.49	144.01	149.07	137.75	180.99
Other Current Assets	17.75M	20.5M	22.38M	27.25M	37.31M	42.53M	49.29M	63.39M	51.02M	61.16M
Total Non-Current Assets+	267.54M	259.73M	256.22M	260.51M	332.26M	342.42M	365.47M	385.67M	381.19M	550.29M
Property, Plant & Equipment	127.32M	127.35M	130.11M	140.24M	170.98M	187.67M	203.17M	231.33M	240.9M	396.03M
Fixed Asset Turnover	5.90x	6.00x	6.30x	5.90x	4.68x	4.44x	4.64x	4.23x	4.22x	3.27x
Goodwill	21.12M	23.98M	27.35M	27.35M	52.68M	52.68M	53.23M	53.27M	54.56M	59.65M
Intangible Assets	60.09M	54.6M	51.98M	47.48M	71M	62.28M	63.86M	54.99M	45.03M	36.47M
Long-Term Investments	9.41M	9.33M	9.18M	9.63M	10.02M	10.11M	10.35M	11.09M	11.49M	11.69M
Other Non-Current Assets	21.57M	21.2M	22.18M	19.05M	16.16M	19.82M	29.02M	26.28M	9.83M	20.91M
Total Assets+	610.37M	623.4M	671.68M	726.67M	784.1M	841.33M	931.7M	971.4M	982.18M	1.36B
Asset Turnover	1.23x	1.23x	1.22x	1.14x	1.02x	0.99x	1.01x	1.01x	1.04x	0.95x
Asset Growth %	0.24%	0.02%	0.08%	0.08%	0.08%	0.07%	0.11%	0.04%	0.01%	0.39%
Total Current Liabilities+	108.78M	115.8M	143.22M	154.23M	157.24M	164.12M	190.83M	176M	204.15M	293.47M
Accounts Payable	60.17M	56.89M	59.5M	73.19M	66.09M	68.36M	95.6M	73.85M	85.57M	138.2M
Days Payables Outstanding	42.85	40.24	39.26	47.42	44.39	44.4	53.12	39.66	44.33	56.28
Short-Term Debt	2.91M	6.25M	12.58M	12.54M	18.75M	9.38M	15M	22.3M	29.8M	16.25M
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	0	0
Other Current Liabilities	34.72M	37.84M	54.67M	43.95M	47M	56.21M	53.18M	48.22M	55.15M	83M
Current Ratio	3.15x	3.14x	2.90x	3.02x	2.87x	3.04x	2.97x	3.33x	2.94x	2.76x
Quick Ratio	1.61x	1.75x	1.66x	1.74x	1.62x	1.72x	1.61x	1.75x	1.64x	1.25x
Cash Conversion Cycle	136.7	133.91	138.74	151.17	145.39	160.41	155.4	170.42	154.2	188.9
Total Non-Current Liabilities+	408.58M	356.44M	343.5M	356.43M	438.66M	438.68M	478.43M	512.89M	521.39M	781.75M
Long-Term Debt	347.26M	306.89M	299.8M	313.63M	368.26M	382.71M	417.93M	452.54M	458.29M	702.43M
Capital Lease Obligations	0	0	0	0	17.28M	28M	31.51M	29.08M	29.91M	33.74M
Deferred Tax Liabilities	8.21M	8.95M	9.73M	8.98M	11.68M	6.65M	9.26M	12.15M	14.22M	19.47M
Other Non-Current Liabilities	53.11M	40.61M	33.97M	33.82M	41.45M	21.32M	19.73M	19.12M	18.97M	26.1M
Total Liabilities	519.89M	472.24M	486.73M	510.66M	595.9M	602.8M	669.26M	688.89M	725.54M	1.08B
Total Debt+	352.71M	313.14M	312.38M	326.18M	410.72M	426.71M	470.48M	509.97M	525.46M	761.55M
Net Debt	319.11M	257.06M	283.21M	268.6M	374.38M	376.49M	396.24M	468.69M	454.85M	693.51M
Debt / Equity	3.90x	2.07x	1.69x	1.51x	2.18x	1.79x	1.79x	1.81x	2.05x	2.67x
Debt / EBITDA	3.23x	2.53x	2.48x	3.23x	4.05x	4.00x	4.21x	4.82x	5.87x	4.88x
Net Debt / EBITDA	2.92x	2.07x	2.25x	2.66x	3.69x	3.53x	3.55x	4.43x	5.08x	4.44x
Interest Coverage	5.09x	5.80x	7.27x	5.36x	4.84x	7.20x	6.53x	4.00x	2.43x	3.32x
Total Equity+	90.48M	151.16M	184.95M	216.01M	188.2M	238.53M	262.44M	282.51M	256.64M	285.68M
Equity Growth %	2.05%	0.67%	0.22%	0.17%	-0.13%	0.27%	0.1%	0.08%	-0.09%	0.11%
Book Value per Share	2.26	3.78	4.58	5.33	4.65	5.89	6.48	6.97	6.33	7.02
Total Shareholders' Equity	90.48M	151.16M	184.95M	216.01M	188.2M	238.53M	262.44M	282.51M	256.64M	285.68M
Common Stock	4K	4K	4K	4K	4K	4K	4K	4K	4K	4K
Retained Earnings	33.96M	82.75M	131.56M	168.93M	183.06M	218.01M	247.75M	260.91M	243.89M	272.7M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-61.78M	-55.44M	-76.48M	-86.18M	-130.38M	-115.29M	-121.11M	-114.21M	-123.53M	-124.02M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Jun 2016	Jun 2017	Jun 2018	Jun 2019	Jun 2020	Jun 2021	Jun 2022	Jun 2023	Jun 2024	Jun 2025
Cash from Operations+	37.22M	98.4M	70.01M	47.17M	59.35M	48.31M	31.65M	13.31M	87.59M	80.12M
Operating CF Margin %	0.05%	0.13%	0.09%	0.06%	0.07%	0.06%	0.03%	0.01%	0.09%	0.06%
Operating CF Growth %	-0.46%	1.64%	-0.29%	-0.33%	0.26%	-0.19%	-0.34%	-0.58%	5.58%	-0.09%
Net Income	82.73M	64.61M	64.88M	54.71M	33.55M	54.38M	49.17M	32.61M	2.42M	48.26M
Depreciation & Amortization	23.45M	26M	26.94M	27.56M	32.34M	31.89M	32.7M	34.01M	36.18M	45.6M
Stock-Based Compensation	0	0	334K	2.26M	2.26M	1.13M	0	0	475K	717K
Deferred Taxes	-22.24M	-28K	6.39M	-105K	8.13M	-2.18M	-806K	-2.84M	-7.84M	-4.88M
Other Non-Cash Items	7.07M	127.7M	6.31M	-1.32M	-3.27M	-7.04M	-4.79M	-9.34M	23.25M	11.98M
Working Capital Changes	-46.06M	1.4M	-33.88M	-35.94M	-13.66M	-29.87M	-44.64M	-41.13M	33.11M	-21.56M
Change in Receivables	-13.09M	-2.77M	-11.9M	-23.68M	28.71M	-18.21M	-23.63M	5.33M	-8.68M	-55.21M
Change in Inventory	-16.44M	5.43M	-24.29M	-20.98M	-12.93M	-12.5M	-47M	-11.22M	2.64M	-44.29M
Change in Payables	-3.25M	-3.12M	2.45M	12.09M	-7.67M	3.18M	26.36M	-22.83M	12M	45.55M
Cash from Investing+	-82.79M	-21.9M	-84.61M	-14.13M	-120.39M	-18.58M	-22.58M	-74.02M	-48.19M	-288.69M
Capital Expenditures	-36.35M	-20.9M	-18.55M	-29.89M	0	-29.32M	-37.04M	-51.79M	-41.24M	-38.29M
CapEx % of Revenue	0.05%	0.03%	0.02%	0.04%	0.04%	0.04%	0.04%	0.05%	0.04%	0.03%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	137K	-1M	-1.06M	-404K	-34.84M	-30.58M	620K	776K	326K	1.13M
Cash from Financing+	50.38M	-53.74M	-11.78M	-4.11M	40.94M	-17M	16.34M	26.99M	-6.77M	207.13M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	-15.71M	-15.83M	-16.07M	-18.59M	-19.42M	-19.43M	-19.44M	-19.44M	-19.44M	-19.45M
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	0	-3.92M	0	0	0	-2.94M	-4.84M	3.74M	-31K	-9.4M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	866K	77.5M	51.46M	17.28M	25.3M	18.99M	-5.39M	-38.48M	46.36M	41.83M
FCF Margin %	0%	0.1%	0.06%	0.02%	0.03%	0.02%	-0.01%	-0.04%	0.05%	0.03%
FCF Growth %	-0.98%	88.49%	-0.34%	-0.66%	0.46%	-0.25%	-1.28%	-6.13%	2.2%	-0.1%
FCF per Share	0.02	1.94	1.27	0.43	0.62	0.47	-0.13	-0.95	1.14	1.03
FCF Conversion (FCF/Net Income)	0.45x	1.52x	1.08x	0.86x	1.77x	0.89x	0.64x	0.41x	36.26x	1.66x
Interest Paid	14.21M	14.6M	11.21M	12.25M	11.58M	10.81M	11.16M	14.57M	17.25M	32.07M
Taxes Paid	16.83M	14.76M	15.19M	16.21M	20.87M	19.39M	17.85M	20.41M	15.43M	13.4M

Key Ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Return on Equity (ROE)	137.71%	53.47%	38.62%	27.28%	16.6%	25.49%	19.63%	11.97%	0.9%	17.8%
Return on Invested Capital (ROIC)	18.38%	17.96%	16.93%	11.54%	9.91%	9.54%	9.3%	7.64%	5.47%	9.8%
Gross Margin	31.8%	32.49%	32.55%	31.96%	32.1%	32.56%	30.29%	30.5%	30.77%	30.85%
Net Margin	11%	8.45%	7.91%	6.61%	4.19%	6.53%	5.22%	3.33%	0.24%	3.72%
Debt / Equity	3.90x	2.07x	1.69x	1.51x	2.18x	1.79x	1.79x	1.81x	2.05x	2.67x
Interest Coverage	5.09x	5.80x	7.27x	5.36x	4.84x	7.20x	6.53x	4.00x	2.43x	3.32x
FCF Conversion	0.45x	1.52x	1.08x	0.86x	1.77x	0.89x	0.64x	0.41x	36.26x	1.66x
Revenue Growth	0.39%	1.7%	7.29%	0.98%	-3.34%	4.12%	13.07%	3.78%	4.07%	27.37%

Revenue by Segment

	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Vaccines	-	-	-	-	-	-	-	100M	120.85M	137.15M
Vaccines Growth	-	-	-	-	-	-	-	-	20.85%	13.49%
Animal Health	-	-	531.73M	68.29M	75.34M	72.94M	607.05M	-	-	-
Animal Health Growth	-	-	-	-87.16%	10.32%	-3.19%	732.28%	-	-	-
Mineral Nutrition	216.69M	218.3M	234.92M	233.78M	214.41M	220.56M	259.51M	-	-	-
Mineral Nutrition Growth	-	0.74%	7.62%	-0.49%	-8.29%	2.87%	17.66%	-	-	-
Performance Products	48.7M	48.24M	53.33M	62.24M	59.04M	67.07M	75.69M	-	-	-
Performance Products Growth	-	-0.95%	10.56%	16.70%	-5.14%	13.61%	12.85%	-	-	-

Revenue by Geography

	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
UNITED STATES	473.25M	484.15M	494.6M	480.1M	-	-	561.8M	578.77M	584.76M	739.92M
UNITED STATES Growth	-	2.30%	2.16%	-2.93%	-	-	-	3.02%	1.03%	26.53%
Latin America and Canada	-	-	-	-	-	-	191.05M	219.85M	247.71M	298.65M
Latin America and Canada Growth	-	-	-	-	-	-	-	15.07%	12.67%	20.57%
EMEA	-	-	-	-	-	-	122.48M	117.81M	121.98M	160.23M
EMEA Growth	-	-	-	-	-	-	-	-3.81%	3.53%	31.36%
Asia Pacific	46.44M	50.48M	51.41M	90.15M	57.3M	58.01M	66.93M	61.45M	63.23M	97.42M
Asia Pacific Growth	-	8.72%	1.83%	75.37%	-36.44%	1.23%	15.39%	-8.18%	2.89%	54.05%
U	-	-	-	-	471.94M	494.89M	-	-	-	-
U Growth	-	-	-	-	-	4.86%	-	-	-	-
Latin America And Canada	105.67M	96.69M	120.85M	152.38M	158.94M	166.32M	-	-	-	-
Latin America And Canada Growth	-	-8.50%	25.00%	26.09%	4.30%	4.65%	-	-	-	-
Europe Middle East And Africa	-	-	-	105.36M	112.18M	114.13M	-	-	-	-
Europe Middle East And Africa Growth	-	-	-	-	6.47%	1.74%	-	-	-	-
ISRAEL	90M	92.75M	109.22M	-	-	-	-	-	-	-
ISRAEL Growth	-	3.06%	17.76%	-	-	-	-	-	-	-
Europe And Africa	36.18M	40.21M	43.9M	-	-	-	-	-	-	-
Europe And Africa Growth	-	11.15%	9.18%	-	-	-	-	-	-	-

Frequently Asked Questions

Valuation & Price

Phibro Animal Health Corporation (PAHC) has a price-to-earnings (P/E) ratio of 33.7x. This suggests investors expect higher future growth.

Growth & Financials

Phibro Animal Health Corporation (PAHC) reported $1.40B in revenue for fiscal year 2025. This represents a 114% increase from $654.1M in 2012.

Phibro Animal Health Corporation (PAHC) grew revenue by 27.4% over the past year. This is strong growth.

Yes, Phibro Animal Health Corporation (PAHC) is profitable, generating $67.8M in net income for fiscal year 2025 (3.7% net margin).

Dividend & Returns

Yes, Phibro Animal Health Corporation (PAHC) pays a dividend with a yield of 1.19%. This makes it attractive for income-focused investors.

Phibro Animal Health Corporation (PAHC) has a return on equity (ROE) of 17.8%. This is reasonable for most industries.

Phibro Animal Health Corporation (PAHC) generated $34.3M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

US Stock Screener

...